

## INDEX

Note: Page numbers in *italics* indicate figures.

Page numbers followed by a “t” indicate tables.

“Take-home messages” can be found at the end of each chapter.

- A- $\beta$  fibers, 16, 17  
A- $\delta$  fibers, 13-15, 16, 17  
Abdominal and pelvic pain, 29, 95-100  
  appendicitis, 96-97  
  bowel obstruction, 97  
  cholecystitis, 97  
  Crohn’s disease, 96  
  diverticulosis/diverticulitis, 96  
  interstitial cystitis, 99  
  irritable bowel syndrome, 98-99  
  ovulatory/menstrual pain, 99-100  
  pancreatitis, 98  
  pelvic pain, 99-100  
  readings on, 106  
  ulcerative colitis, 95  
Acetaminophen (APAP, Tylenol), 115-116  
  APAP-containing opioids (Darvocet, Endocet, Percocet, Tylenol  
    with codeine, Vicodin), 116, 139t-141t, 147, 207  
  contraindications and cautions, 215t  
  fixed-dose combinations  
    APAP/codeine (Tylenol with codeine), 139t, 147  
    hydrocodone/APAP (Hycet, Lortab, Vicodin, Zydone),  
      139t-140t, 147  
    pentazocine/APAP (Talacen), 141t  
    tramadol/APAP (Ultracet), 141t  
  hepatotoxicity of, 115-116  
  indications and usages, 115  
    cancer-related pain, 207  
    lumbar spinal stenosis, 74  
    migraine headache, 127  
    older people, use in, 214, 215t  
Actiq. See *Fentanyl citrate*.  
Acupuncture, 175-176, 200  
Acute pain  
  duration and characteristics of, 26-27  
  psychosocial risk factors in, 54, 55t  
  recurrent, 27  
  toxic consequences of, 27  
  vs chronic pain, 26, 27  
*Acute Pain* (journal), 255  
Adaptive pain, 11  
Addiction-medicine specialists, 244  
Adolescents. See *Children and adolescents*.  
Adson’s test, 81  
Age. See also *Older people*.  
  changes in organ systems with, 213t  
  chronic pain and, ix, 214  
  low back pain and, 187t  
AIDS-related neuropathies, 88  
Alcohol abuse. See also *Substance abuse*.  
  assessment of, 40-41, 54  
Allodynia, 18, 20  
Almotriptan (Axert), 127, 128t  
 $\alpha$ -Adrenergic agonists, 22, 23, 174  
 $\alpha$ -Adrenergic blockers, 90  
 $\alpha$ 2 $\delta$  Ligands, 200, 200t  
Amerge. See *Naratriptan*.  
American Academy of Orofacial Pain (AAOP), 247  
American Academy of Pain Management (AAPM), 248  
  recommendations for opioid therapy, 144t-146t  
American Academy of Pain Medicine (AAPM), 248  
American Arthritis Society, 251  
American Board of Pain Medicine, 242  
American Cancer Society (ACS), 251  
American Chronic Pain Association (ACPA), 253  
American Headache Society (AHS), 251  
American Pain Foundation (APF), 253  
American Pain Society (APS), 248  
  recommendations for opioid therapy, 144t-146t  
American Society of Interventional Pain Physicians (ASIPP), 248  
American Society of Pain Educators (ASPE), 249  
American Society for Pain Management Nursing (ASPMN), 249  
American Society of Regional Anesthesia and Pain Medicine  
  (ASRA), 249  
Amitriptyline (Elavil, others), 121, 122t, 216t  
  for headache, 182, 183, 184  
AMPA receptors, 16, 17  
Amrix. See *Cyclobenzaprine*.  
Amygdala, 18, 19  
Analgesia  
  Analgesic Ladder, Three-Step (WHO), 205-207, 206  
  sites of action of pharmacologic agents, 22, 23  
Anesthesiologists, 243, 245  
Anesthetics  
  local, 131-133  
  for phantom limb pain, 90  
Angina, 93, 93t  
Ansaïd. See *Flurbiprofen*.  
Anterior cingulate cortex, 18, 19  
Anti-inflammatory agents, 116-120  
  corticosteroids, 120  
  nonsteroidal agents, 116-120  
Anticholinergics, for esophageal motility disorders, 95

Anticonvulsants, 124-126, 125t  
 classes of, 124, 125t  
   calcium channel modulators, 125t  
   GABAergic and mixed actions, 125t  
   sodium channel modulators, 125t  
 indications and uses, 124, 125t, 126  
 cancer-related pain, 207  
 CRPS, 80  
 headache, 68, 127, 128t, 183  
 low back pain, 189, 191  
 peripheral artery disorders, 91  
 phantom limb pain, 91  
 postherpetic neuralgia, 87, 125t, 201, 202  
 radiation-induced pain, 105  
 thoracic outlet syndrome, 81  
 vulvodynia, 102  
 site of action of, 22, 23

Antidepressants, 120-124, 122t-123t  
 agents and dosages, 122t-123t  
 atypical, 123t, 124  
 indications and usages, 120-124  
 AIDS-related neuropathies, 88  
 cancer-related pain, 207  
 headache, 68, 182  
 low back pain, 189, 191  
 neuropathic pain, 195, 196t  
 phantom limb pain, 91  
 postherpetic neuralgia, 87, 88, 121, 201, 202  
 radiation-induced pain, 105  
 vulvodynia, 102  
 selective serotonin reuptake inhibitors (SSRIs), 121, 122t  
 serotonin and norepinephrine reuptake inhibitors (SNRIs),  
 121-124, 123t  
 site of action of, 22, 23  
 tricyclic, 120-121, 122t. See also *Tricyclic antidepressants*.

Antihistamines, for vulvodynia, 102

Antimalarials, for rheumatoid arthritis, 84

Antimigraine agents, 125t, 127, 128t

Antipsychotics, 127-129, 207

Antispasitics/muscle relaxants, 129-131, 130t

Anxiety, antidepressants for, 121

Anxiety assessment, 39  
 Beck Anxiety Index (BAI), 39  
 Hamilton Anxiety (HAM-A) Scale, 39

Anxiolytics, 126-127

APAP. See *Acetaminophen*.

Appendicitis, 96-97

Arachidonic acid (AA), 20, 21

Aripiprazole, 129

Arthritis Foundation, 253

Arthrography, 52

Arthropathies, 81-86  
 gout, 85-86  
 osteoarthritis, 81-83  
 reactive arthritis, 84-85  
 readings on, 106-107  
 rheumatoid arthritis, 83-84  
 societies and associations for, 251, 253

Arthrotec. See *Diclofenac*.

Aspirin (Ecotrin, others), 116-117, 118t  
 indications and usages, 116, 127, 182  
 oxycodone/aspirin (Percodan, Endodan), 140t

Assessment depression and anxiety, 37-39

Assessment of pain, 33-44  
 Brief Pain Inventory (BPI), 36-37  
 in children, 218-220, 219t  
 initial pain assessment tool, 36  
 McGill Pain Questionnaire (MPQ), 37  
 monodimensional scales, 33-36, 34. See also *Pain scales*.  
 multidimensional tools, 36-37  
 in older people, 211-212  
 substance abuse screening with, 39-43  
 tools for, 33-37, 34

Assessment of psychosocial functioning, 54-55, 55t

Assessment of substance abuse/potential, 39-43, 234-236  
 alcohol abuse screening tools, 40-41  
 drug abuse screening tools, 39-43  
 opioid abuse screening tools, 41-43

Associations, organizations, and societies, 247-252

Atomoxetine, 133

Atypical antidepressants, 123t, 124

Avinza. See *Morphine, controlled-release*.

Avoidance responses, 15

Axert. See *Almotriptan*.

Back pain, 68-76. See also *Low back pain*.  
 treatment of, 185-191

Baclofen, 129-131, 130t

BDNF, 17

Beck Anxiety Index (BAI), 39

Beck Depression Inventory (BDI), 38

Behavioral interventions, 171  
 for headache, 184

Behavioral therapy, 171, 200, 202

Benzocaine, 131

Benzodiazepines, 126-127

$\beta$ -Adrenergic blockers  
 for angina/MI, 93  
 for headache, 68, 127, 183

Biofeedback, 51, 170

Bisphosphonates, for bone metastases, 102  
 BK (bradykinin) receptor, 20  
 Bone metastases, 102  
 Books on pain, 260-261  
 Botulinum toxin, 130t, 131  
   indications and usages, 131  
   esophageal motility disorders, 95  
   headache, 68, 127, 131  
 Bowel obstruction, 97  
 Bradykinin (BK), 18, 21  
 Bradykinin (BK) receptor, 20  
 Brain  
   neuroplasticity, 18-20  
   pain processing centers in, 18, 19  
 Breakthrough pain, in cancer patients, 135, 136t, 207, 223  
 Brief Pain Inventory (BPI), 36-37  
 Bupivacaine, 131  
 Bupropion (Wellbutrin), 123t, 124  
 Buspirone, 127  
 Butalbital, 127  
 Butorphanol (Stadol), 134, 141t, 143  
  
 C-fibers, 13, 15, 16, 17  
   overexpression of sodium channels on, 20, 21  
   TENS action on, 169  
 C-reactive protein (CRP), 85  
 Caffeine, for headache pain, 127, 133, 183, 184  
 CAGE-AID, 40-41  
 Calcitonin  
   for CRPS, 80  
   for phantom limb pain, 91  
 Calcium channel blockers/modulators, 124-126, 125t  
   indications and usages, 125t  
   angina/MI, 93  
   diabetic neuropathic pain, 200, 200t  
   esophageal motility disorders, 95  
   headache, 68, 127  
   neuropathic pain, 195, 196t  
   postherpetic neuralgia, 201, 202  
   Raynaud's phenomenon, 92  
   intrathecal delivery of, 175  
 Canadian Pain Society (CPS), 249-250  
 Cancer  
   headache with, 70t  
   society for, 251  
 Cancer patients  
   palliative care for, 28, 222-223  
   terminally ill, 223-224  
  
 Cancer-related pain, 102-105  
   bone metastases, 102  
   differentiation from noncancer pain, 28  
   diversity/spectrum of, 205  
   evaluation/algorithm for, 206  
   pancreatic cancer, 103  
   paraneoplastic syndromes, 104  
   plexopathy, 104  
   radiation-induced pain, 104-105  
   readings on, 108  
   soft tissue involvement, 103  
   spinal cord compression, 102-103  
   terminally ill patients, 222-223  
   treatment options, 27, 205-208, 206  
     for breakthrough pain, 135, 136t, 207, 223  
     with disease remission, 28  
     palliative care, 28, 222-223  
     surgical methods, 208  
   WHO Three-Step Analgesic Ladder for, 205-207, 206  
 Capsaicin, 132-133  
   indications and usages, 87, 132, 201-202, 202  
   patch (Qutenza), 133, 201, 202  
 Carbamazepine (Tegretol, Tegretol-XR), 125t, 126, 201, 202  
 Cardiac/central chest pain, 92-94, 93t  
 Carisoprodol (Soma, others), 129, 130t  
 Carpal tunnel syndrome, 76-79, 203-204  
   treatment of, 77-78, 204  
 Categorical scales for pain, 34, 35-36  
 Cauda equina syndrome, 72-73, 90, 187t, 189, 190  
 Causalgia. See *Complex Regional Pain Syndrome type 2*.  
 Causes of pain, 11-13, 12, 28-29  
 Celebrex. See *Celecoxib*.  
 Celecoxib (Celebrex), 117, 119t  
 Celexa. See *Citalopram*.  
 Celiac block, 103  
 Central pain modification failure, 29, 100-102  
   fibromyalgia, 100-101, 101t  
   interstitial cystitis and, 99  
   irritable bowel syndrome and, 98  
   readings on, 109  
   temporomandibular joint disorder, 101  
   vulvodynia, 102  
 Central perception of pain, 16-17  
   analgesic medications and, 23  
 Central sensitization, 16-17  
 Cervicogenic headaches, 65-66  
   treatment of, 131  
 Chemical sensitivities, 29

Chest pain  
 cardiac/central chest, 92-94, 93t  
 nonvascular, 94-95  
 readings on, 108

Children and adolescents, 217-222  
 pain assessment in, 218-220, 219t, 221-222  
 FLACC Scale, 218, 219t  
 infants and preverbal children, 218, 219t, 221-222  
 pain management in, 220-222

Chiropractic manipulation, 74, 175-176

Chloroprocaine, 131

Chlorpromazine, 129

Chlorzoxazone (Parafon Forte DSC), 129, 130t

Cholecystitis, 97

Chronic daily headache, 66-67

Chronic pain  
 age and, ix, 214  
 cancer. See *Cancer-related pain*.  
 cancer vs noncancer, 28  
 consequences of, 27  
 duration and characteristics of, 26, 27  
 management of, 27  
 noncancer (CNCP), 28, 144t-146t  
 pelvic, 99-100  
 psychosocial risk factors in, 54, 55t  
 societies and associations for, 253-255  
 treatment of  
 cancer, 27, 28  
 low back, 190-191, 192-193  
 noncancer, 27, 143, 144t-146t  
 vs acute pain, 26, 27

Citalopram (Celexa, others), 122t

Classification of headache, 58, 59t

Classification of pain, 11-13, 25-32  
 acute vs chronic, 26-27  
 criteria for  
 intensity of pain, 30  
 location of pain, 26, 28-29  
 temporal characteristics, 26-27  
 underlying pathology, 28-30  
 what we do not understand, 25  
 primary types of pain, 11-13, 12  
 reality of pain/placebo use, 30-31  
 subacute or recurrent, 27

*Clinical Journal of Pain, The*, 255

Clinical trials of new agents/indications, 147-162

Clinoril. See *Sulindac*.

Clonazepam, 126

Clonidine, 174, 195

Cluster headache, 64-65, 65t  
 treatment of, 131, 184, 185

Codeine, 134, 135  
 fixed-dose combination (codeine/APAP), 139t, 147  
 immediate-release, 134, 136t

Cognitive behavioral therapy (CBT), 171, 200, 202

Colchicine, 86

Common pain syndromes. See *Pain syndromes*.

Complex regional pain syndrome (CRPS), 79-80  
 treatment of, 80, 173  
 type 1 (formerly reflex sympathetic dystrophy), 28, 31, 79-80  
 type 2 (formerly causalgia), 28, 79, 80

Complimentary and alternative medicine (CAM), 175-176

Computed tomography (CT), 50-51  
 for headache, 61-62  
 for low back pain, 73, 190

Constipation, from opioid therapy, 143-147, 207-208

Controlled-substance prescribing. See *Medicolegal considerations*.

Corticosteroids, 120  
 indications and usages, 120  
 cancer-related pain, 207  
 gout, 86  
 herniated disk, 74  
 pericarditis, 94  
 plexopathy, 104  
 spinal cord compression, 103  
 older people, use in, 216t

Cost-burden of pain, ix

COX (cyclooxygenase), 20, 21

COX-2 inhibitors (Celebrex), 22, 23, 117, 119t  
 older people, use in, 214, 215t

Cranial neuralgia, 59t

Crohn's disease, 96

CRPS. See *Complex regional pain syndrome*.

Cryotherapy, 169

Cubital tunnel syndrome, 78

*Current Pain and Headache Reports* (journal), 255

Cushing's syndrome, 172

Cyclobenzaprine (Flexeril, Amrix, others), 129, 130t

Cymbalta. See *Duloxetine*.

Cystitis, interstitial, 99

Cytokines, 20, 21

Darvocet (propoxyphene/APAP), 141t

Darvon (propoxyphene), 135, 137t

DAST (Drug Abuse Screening Test), 41

Daypro. See *Oxaprozin*.

Deep-brain stimulation, 197

Demerol. See *Meperidine*.

Denervation, surgical, 174

Depakote ER. See *Divalproex*.

Depression  
 antidepressants for, 121-124  
 assessment of, 37-39  
   Beck Depression Inventory (BDI), 38  
   Hamilton Depression Rating Scale (HAM-D), 37-38  
   Zung Self-Rating Depression Scale, 38-39

Descending inhibitory control, 13, 16, 17  
 failure of, 29

Desipramine (Norpramin), 122t, 196t, 200t

Desvenlafaxine (Pristiq), 123t, 124

Desyrel. See *Trazodone*.

Dexamethasone, 120

Dextroamphetamine, 133

Diabetic neuropathy, 86-87  
 pregabalin for, 126  
 TCAs for, 121

Diabetic peripheral neuropathic pain (DPNP), 150-152, 197-200  
 clinical presentations, 87, 198-199  
 treatment options, 197-200, 200t  
   antidepressants, 124, 200, 200t  
   calcium channel modulators, 125t, 200, 200t  
   capsaicin, 132  
   duloxetine, 124, 150-152, 152, 200t  
   new agents and indications, 150-152, 152, 153  
   opioid agonists, 200, 200t  
   pregabalin, 152, 153, 200t

Diagnosis of pain patient. See *Evaluation and diagnosis*.

Diagnosis, Intractability, Risk, and Efficacy (DIRE) Score, 41-42

Diathermy, 169

Diazepam, 126

Diclofenac (Arthrotec, Flector, Pennsaid, Solaraze, Voltaren, Zipsor), 117, 118t  
 formulations and dosages, 117, 118t  
 topical formulations, 117  
 indications and usages, 117

Dilaudid. See *Hydromorphone*.

Dimethyl sulfoxide, for CRPS, 80

Diplopia, 179

DIRE (Diagnosis, Intractability, Risk, and Efficacy) Score, 41-42

Disability, psychosocial factors for development of, 55t

Disease-modifying antirheumatic drugs (DMARDs), 83-84, 85

Disk herniation, 73-74

Diskography, 52

Divalproex (Depakote ER), 125t

Diverticulosis/diverticulitis, 96

DMARDs. See *Disease-modifying antirheumatic drugs*.

Documentation, 233-234

Dolophine. See *Methadone*.

Dorsal horn, 15-17, 16, 17

Dorsal root entry zone (DREZ) lesioning, 197, 202

Doxepin (Sinequan), 122t, 216t

DREZ lesioning, 197, 202

Drug Abuse Screening Test (DAST), 41

Drug abuse. See *Substance abuse*.

Drug Enforcement Agency (DEA), 234-236

Drugs. See *Pharmacologic treatment of pain*.

Duloxetine (Cymbalta), 123t, 124  
 for diabetic peripheral neuropathic pain, 124, 150-152, 152, 200t  
 for fibromyalgia, 124, 148-149, 150  
 for neuropathic pain, 196t

Duragesic. See *Fentanyl*.

Ecotrin. See *Aspirin*.

Effexor. See *Venlafaxine*.

Elavil. See *Amitriptyline*.

Elderly patients. See *Older people*.

Electrodiagnostic tests, 52-53  
 for carpal tunnel syndrome, 204  
 for low back pain, 73

Electromyography (EMG), 52

Eletriptan (Relpax), 127, 128t

Embeda, Embeda ER (morphine/naltrexone), 140t, 162, 163

Endocet (oxycodone/APAP), 116, 140t

Endodan (oxycodone/aspirin), 140t

Entrapment neuropathies, 76-79, 203-204  
 carpal tunnel syndrome, 76-79, 203-204  
 cubital tunnel syndrome, 78  
 pronator syndrome, 77-78  
 treatment of, 77-78, 203-204  
 ulnar tunnel syndrome, 204

Epidural steroid injections, 74, 172

Ergot derivatives, for headache, 68, 127, 183, 184, 185

Erythromelalgia, 91

Escitalopram (Lexapro), 122t

Esophageal motility disorders, 95

Eszopiclone, 127

Ethnic and racial minorities, 222-223

Etidocaine, 131

Etodolac, etodolac ER (Lodine, Lodine XL), 118t

*European Journal of Pain*, 255

Evaluation and diagnosis, 45-56  
 diagnostic studies and interventions, 50-54  
   electrodiagnostic tests, 52-53  
   imaging studies, 50-52  
   neural blockade, 53-54  
 dual-diagnosis patients, 224  
 history, 45-46, 47t, 179-182  
 laboratory/diagnostic testing, 49-54  
 laboratory studies, 49-50

Evaluation and diagnosis (*continued*)  
physical examination, 46, 48t-49t  
PQRST mnemonic, 46  
psychosocial assessment, 54-55, 55t  
Exalgo. See *Hydromorphone*.  
Examinations. See *Evaluation and diagnosis*.  
Exercise, 168, 191, 200  
Extremity pain, 76-81  
complex regional pain syndrome (CRPS), 79-80  
repetitive stress/strain and entrapments, 76-79, 203-204  
thoracic outlet syndrome, 80-81

Faces Pain Scale (FPS) for Adults and Children, 34, 35-36, 220  
Facial pain, 59t  
Facial Pain Association, The, 251  
Failure of central pain modification. See *Central pain modification failure*.  
FDA (Federal Drug Administration), 236-237  
FDAAA (FDA Amendment Act, 2007), 236-237  
Federation of State Medical Boards requirements, 228-230  
Feldene. See *Piroxicam*.  
Fentanyl, 134-135, 142, 147, 207  
controlled-release (Duragesic), 134, 135, 137t, 207  
ultra-rapid acting (fentanyl/fentanyl citrate), 134, 135, 136t, 154-156, 223  
Fentanyl citrate (Actiq, Fentora, others), 134, 136t, 154-156, 223  
buccal tablets (FBT; Fentora), 136t, 154, 155  
dosages and cautions, 136t, 154  
FBSF (Onsolis), 134, 135, 136t, 156, 156  
oral transmucosal (OTFC; Actiq, others), 134, 136t, 154  
Fentora. See *Fentanyl citrate*.  
Fibromyalgia, 100-101  
causes of, 29, 100  
clinical features of, 100, 101t  
societies and associations for, 252, 253-254  
treatment of, 101  
duloxetine, 124, 148-149, 150  
milnacipran, 124, 149-150, 151  
muscle relaxants, 129  
new agents and indications, 147-150, 148, 149  
pregabalin, 125t, 126, 147-148, 148, 149  
FLACC Scale, 218, 219t  
Flector. See *Diclofenac*.  
Flexeril. See *Cyclobenzaprine*.  
Flick sign, 76  
Fluoxetine (Prozac), 122t  
Flurbiprofen (Ansaid), 118t  
Fluvoxamine (Luvox, others), 122t  
Food and Drug Administration (FDA), 236-237  
Frovatriptan (Frova), 127, 128t

Functional MRI (fMRI), 51  
Functional pain, 12, 13

GABAergic and mixed action anticonvulsants, 124-126, 125t  
Gabapentin (Neurontin), 125t  
indications and usages  
AIDS-related neuropathies, 88  
neuropathic pain, 196t, 200, 200t  
postherpetic neuralgia, 87, 125t, 126, 201, 202  
Gastroesophageal reflux, 94-95  
Geriatric patients. See *Older people*.  
GI protection, 215t  
Glutamate, 15, 16, 17  
Golden 100 days, 27  
Gout, 85-86

Haloperidol, 129  
Hamilton Anxiety (HAM-A) Scale, 39  
Hamilton Depression Rating Scale (HAM-D), 37-38  
Headache and neck pain, 58-68. See also *Headache treatment*.  
cervicogenic headaches, 65-66  
chronic daily headache, 66-67  
classification of headache, 58, 59t  
cluster headache, 64-65, 65t  
frontotemporal headache, unilateral, 182  
history, 58-61, 60t, 179-182  
imaging studies for, 61-62  
medication overuse headache, 66, 67  
migraine headache, 62-64, 63t, 183  
other causes, 59t, 66, 68  
physical examination, 61, 182  
primary vs secondary headaches, 58, 59t  
readings on, 109-111  
rebound headache, 182  
red flags in diagnosis of, 68, 70t-71t  
societies and organizations for, 251, 254  
tension-type headache, 64, 64t  
"thunderclap" headache, 61, 70t, 179  
treatment of. See *Headache treatment*.  
vascular headaches, 62-64, 182-183  
worsening pattern of, 70t  
Headache treatment, 179-185, 180-181  
algorithm/management strategy, 180-181  
antimigraine agents, 125t, 127, 128t  
cluster headache, 131, 184, 185  
general considerations, 68  
migraine headache, 183, 184  
tension headache, abortive/prophylactic treatment, 182  
vascular headaches, 182-185, 184  
Heat/ice packs, 168

*Helicobacter pylori*, 215t  
Herniated lumbar disk, 73-74, 187  
Herpes zoster (shingles), 87, 201. See also *Postherpetic neuralgia*.  
Hippocampus, 18, 19  
History, 45-46, 47t  
    headache, 58-61, 60t, 179-182  
    low back pain, 186-190, 187t  
    medication, 46, 47t  
Hospice, 147, 223-224  
Hycet. See *Hydrocodone/APAP*.  
Hydrocodone, 134, 135, 147  
Hydrocodone/APAP (Hycet, Lortab, Vicodin, Zydone), 139t-140t, 147  
Hydrocodone/ibuprofen (Vicoprofen), 140t  
Hydrocortisone, 120  
Hydromorphone, 134, 135, 142  
    controlled/extended-release (Exalgo), 137t, 160-161, 161  
    high-concentration, 147  
    immediate-release (Dilaudid, others), 134, 136t  
    ultra rapid-acting (Dilaudid, others), 134, 136t  
Hyperalgesia, 13, 18  
Hyperarousal, 29  
Hypothalamus-pituitary axis, 172  
  
Ibuprofen (Motrin), 118t  
    hydrocodone/ibuprofen (Vicoprofen), 140t  
Imaging studies  
    for headache evaluation, 61-62, 182  
    for pain evaluation, 50-52  
Imipramine (Tofranil-PM), 122t, 216t  
Imitrex. See *Sumatriptan*.  
Implantable drug-delivery system (IDDS), 174-175  
Inadequate pain management, consequences of, x  
Incarcerated individuals, 224-225  
Indocin, Indocin-SR. See *Indomethacin*.  
Indomethacin, indomethacin-SR (Indocin, Indocin-SR), 118t  
Infants, pain assessment in, 218, 219t, 221-222  
Inflammatory pain, 12-13, 12, 28-29. See also *Anti-inflammatory agents*.  
    somatic vs visceral, 28-29  
Influenza vaccination, 84  
Inhibitory mechanisms (modulation), 13, 17  
    failure of, 29, 100-102. See also *Central pain modification failure*.  
Initial pain assessment tool, 36  
Injuries of nerves/nervous system. See *Neuropathic pain*.  
Insular cortex, 18, 19  
Intensity of pain  
    classification by, 30  
    continuum of, 30  
Interleukin 1- $\beta$  (IL-1 $\beta$ ), 20, 21  
International Association for the Study of Pain (IASP), 250

International MYOPAIN Society (IMS), 250  
Interstitial cystitis, 99  
Interventional therapies, 171-175. See also *Nonpharmacologic and interventional therapies*.  
Intrathecal drug delivery, 174-175  
Irritable bowel syndrome, 98-99  
Isometheptene, 127, 183, 184  
  
Journals and publications on pain, 255-259  
*Journal of Musculoskeletal Pain* (JMS), 256  
*Journal of Opioid Management*, 256  
*Journal of Orofacial Pain*, 256  
*Journal of Pain and Palliative Care Pharmacotherapy*, 256  
*Journal of Pain, The*, 256  
  
Kadian. See *Morphine, controlled-release*.  
Ketamine, 132, 174-175  
Ketoprofen, ketoprofen-SR (Orudis, Oruvail), 118t  
  
Laboratory/diagnostic testing, 49-54  
Lamotrigine, 88  
Laws. See *Medicolegal considerations*.  
Laxatives, with opioid therapy, 143-147, 208  
Legal issues. See *Medicolegal considerations*.  
Levo-Dromoran. See *Levorphanol*.  
Levorphanol (Levo-Dromoran), 134, 139t, 142, 200t  
Lexapro. See *Escitalopram*.  
Lidocaine, 54, 131, 132  
    indications and usages  
        headache, 184, 185  
        neuropathic pain, 195, 196t, 200, 200t, 216t  
        postherpetic neuralgia, 87, 201, 202  
        patch formulation (Lidoderm), 132, 200, 200t  
Lidoderm, 132. See also *Lidocaine*.  
Local anesthetics, 131-133. See also *Capsaicin*; *Lidocaine*.  
    administration methods, 132  
    for diagnostic neural blockade, 53-54  
Location of pain  
    classification by, 26, 28-29  
    in physical examination, 48t  
Lodine, Lodine XL, 118t. See also *Etodolac*.  
Lortab. See *Hydrocodone/APAP*.  
Low back pain (LBP), 68-76  
    cauda equina syndrome, 72-73  
    causes of, 68-73, 190t  
        red flags/life-threatening causes, 69-72, 72t, 187t  
    clinical features of, 68-69  
    cost of, 68  
    diagnostic studies for, 73  
    herniated lumbar disk, 73-74, 187

- Low back pain (LBP) (*continued*)  
 history and exam for, 186-190  
 red flags in, 187t  
 lifetime occurrence of, 68  
 lumbar facet syndrome, 75  
 lumbar radiculopathy, 68-73  
 lumbar spinal stenosis, 74-75  
 readings on, 107  
 risk factors for serious underlying disease, 72t  
 sacroiliac joint dysfunction, 75-76  
 self-limiting nature of, 185  
 treatment of, 185-191  
   acute LBP, 186-190, 188-189  
   chronic LBP, 190-191, 192-193  
   conservative, 196  
   tizanidine, 131
- Lumbar disk, herniated, 73-74, 187
- Lumbar facet syndrome, 75
- Lumbar puncture, 182
- Lumbar radiculopathy, 68-73
- Lumbar spinal stenosis, 74-75
- Lung diseases, 94
- Luvox. See *Fluvoxamine*.
- Lyrica. See *Pregabalin*.
- Macrophages, 20, 21
- Magnetic resonance imaging (MRI), 51  
 functional (fMRI), 51  
 for headache, 62  
 for low back pain, 73, 190
- Maladaptive pain, 11
- Massage, 168, 176, 191, 200
- MAST. See *Michigan Alcoholism Screening Test*.
- Maxalt, Maxalt-MLT. See *Rizatriptan*.
- McGill Pain Questionnaire (MPQ), 37
- MDNG: Pain Management* (journal), 259
- Meclofenamate, 118t
- Medical Outcome Study Short-Form 36, 36, 54
- Medication overuse headache (MOH), 66, 67
- Medications. See *Pharmacologic treatment of pain*.
- Medicine, laws, and regulations. See *Medicolegal considerations*.
- Medicolegal considerations, 227-239  
 authority of states, 227  
 documentation, 233-234  
 Drug Enforcement Agency, 234-236  
 FDA and FDAAA, 236-237  
 Federation of State Medical Boards requirements, 228-230  
 pain-management medicine, 227-228  
 responsibilities of the prescriber, 230-233
- Meetings on pain (annual, US), 259
- Meloxicam (Mobic), 118t
- Menstrual pain, 99-100
- Meperidine (Demerol), 136t
- Mepivacaine, 131
- Metaxalone (Skelaxin), 129, 130t
- Methadone (Dolophine), 134, 139t, 142, 200t, 237  
 cautions on, 144t, 216t
- Methocarbamol, 129, 130t
- Methotrexate, 84
- Methylphenidate, 133
- Methylprednisolone, 120, 202, 202
- Mexiletine, 88
- Michigan Alcoholism Screening Test (MAST), 41
- Microglial cells, 15, 17
- Midline chest pain, 92-94, 93t
- Midrin, 183, 184
- Migraine headache, 62-64, 63t  
 treatment of, 127, 128t, 183, 184  
   abortion, 127, 128t, 183  
   fixed-dose combination agents, 127  
   prophylaxis/prevention, 125t, 126, 127, 183  
   with vs without aura, 62-64, 63t, 183
- Military personnel with combat trauma, 224
- Milnacipran (Savella), 123t, 124  
 for fibromyalgia, 149-150, 151
- Minerals, for headache, 68, 127
- Mini-Mental State Examination (MMSE), 54
- Minnesota Multiphasic Personality Inventory (MMPI), 54
- Minorities, 222-223
- Mirtazepine, 121
- Mittelschmerz, 99
- Mobic. See *Meloxicam*.
- Modafinil, 133
- Molecular Pain* (journal), 257
- Monoamine oxidase inhibitors (MOAIs), 124
- Morphine, 134, 147, 200t  
 controlled-release (Avinza, Kadian, Oramorph SR, MS Contin),  
 138t, 142  
 fixed-dose combination (morphine/naltrexone, Embeda),  
 140t, 162, 163  
 immediate-release, 137t  
 ultra rapid-acting, 134, 136t
- Motrin. See *Ibuprofen*.
- MRI. See *Magnetic resonance imaging*.
- MS Contin. See *Morphine, controlled-release*.
- Muscle relaxants, 129-131, 130t  
 for low back pain, 189, 191
- Musculoskeletal system examination, 49t
- Myelography, 52
- Myocardial infarction (MI), 93, 93t



Myofascial pain, 95, 111  
 society for, 250  
 treatments of, 131  
 Myopathies, 50

Nabumetone (Relafen), 119t  
 Nalbuphine (Nubain), 134, 141t, 143  
 Naloxone, 134  
 Naloxone/pentazocine (Talwin NX), 141t  
 Naltrexone, 134  
 Naltrexone/morphine (Embeda), 140t, 162, 163  
 Naprosyn. See *Naproxen*.  
 Naproxen (Naprosyn), 119t  
   sumatriptan/naproxen (Treximet), 127, 128t  
 Naratriptan (Amerge), 127, 128t  
 Narcotic, terminology, 133  
 National Fibromyalgia Association (NFA), 253-255  
 National Fibromyalgia Research Association (NFRA), 252  
 National Headache Foundation (NHF), 254  
 National Vulvodynia Association (NVA), 252  
 Neck pain. See *Headache and neck pain*.  
 Nerve blocks, diagnostic, 53-54  
 Nerve conduction studies (NCSs), 53  
 Nerve conduction velocity (NCV) measurements, 50, 53  
 Nerve growth factor (NGF), 20, 21  
   for AIDS-related neuropathies, 88  
 Nerve injuries. See *Neuropathic pain*.  
 Nerve roots  
   compression of, 72-73  
   pain of, 68-76  
   surgical denervation, 174  
 Neuralgia  
   cranial, 59t  
   postherpetic, 201  
   trigeminal, 125t, 126  
 Neurobiofeedback, 51  
 Neurogenic claudication, 74  
 Neurologic examination, 48t-49t  
 Neurontin. See *Gabapentin*.  
 Neuropathic pain, 12, 13, 194-195  
   causes of, 194  
   characteristics of, 29  
   classification of, 28, 29  
   diabetic peripheral neuropathic pain (DPNP), 150-152, 197-200  
   postherpetic neuralgia, 87-88, 201  
   red flags for further investigation/referral, 184t  
   societies and associations for, 254-255  
   subtypes of, 29  
     Complex Regional Pain Syndromes type 1 and type 2, 28

Neuropathic pain (*continued*)  
 treatment of, 29, 195-202, 196t  
   antidepressants, 121-124  
   DPNP, 197-200, 200t  
     new agents and indications, 150-152, 152, 153  
   lidocaine, 195, 196t, 200, 200t, 216t  
   postherpetic neuralgia, 201-202, 202  
   spinal cord stimulation, 173, 197, 200  
   stepwise approach, 195, 196t  
 Neuropathic Pain Network (NPN), 254  
 Neuropathies, 86-91  
   AIDS-related, 88  
   diabetic, 86-87, 150-152, 197-200  
   entrapment, 76-79, 203-204  
   peripheral, 29  
   phantom limb pain, 90-91  
   postherpetic neuralgia (PHN), 87-88  
   radiation, 90  
   readings on, 111-112  
   toxic, 88-89, 89t  
 Neuropathy Association, Inc., The, 254-255  
 Neuroplasticity, 18-20  
 Nitrates  
   for angina/MI, 93  
   for esophageal motility disorders, 95  
 Nitroglycerin  
   for esophageal motility disorders, 95  
   topical, for Raynaud's phenomenon, 92  
 NK-1 receptors, 17  
 NMDA receptor-antagonists, 91  
 NMDA receptors, 16-17, 17  
 Nociceptive pain, 11-12, 12  
   adaptive quality of, 11-12  
   classification of, 28-29  
   processing steps, 13-18, 14  
   second-order neurons and, 15-16, 16, 17  
 Nociceptors, changes in, 18-20, 21  
 Noncancer pain, chronic (CNCP), 28, 144t-146t  
 Noninflammatory/nonneuropathic (functional) pain, 12, 13  
 Nonpharmacologic and interventional therapies, 167-178  
   biofeedback, 170  
   complimentary and alternative medicine, 175-176  
   interventional therapies, 171-175  
     intrathecal drug delivery, 174-175  
     spinal cord stimulation, 173  
     steroid injections, 172  
     surgical denervation, 174  
     trigger-point injections, 171-172  
   overview, 167  
   physical/occupational therapy, 167, 168

Nonpharmacologic and interventional therapies (*continued*)

- psychological/behavioral interventions, 167, 171
- thermal modalities, 168-169
- transcutaneous electrical nerve stimulation (TENS), 169-170
- Nonsteroidal anti-inflammatory agents, 116-120
  - older people, use in, 214, 215t
- Nonsteroidal anti-inflammatory drugs (NSAIDs), 117-120, 118t-119t
  - actions of, 117
    - sites of action, 22, 23
  - agents and dosages, 118t-119t
  - contraindications and cautions, 215t
  - COX-2 selective, 117, 119t
  - indications and uses, 117
    - carpal/ulnar tunnel syndrome, 204
    - CRPS, 80
    - gout, 86
    - headache, 68, 127, 182
    - herniated disk, 74, 187
    - low back pain, 189, 191
    - lumbar spinal stenosis, 74
    - osteoarthritis, 82
    - reactive arthritis, 85
    - rheumatoid arthritis, 84
    - topical agents, 117
    - nonselective, 118t-119t
    - side effects, 117-120
- Nonvascular pain, 94-95
  - chest, 94-95
  - esophageal motility disorders, 95
  - gastroesophageal reflux, 94-95
  - myofascial pain, 95
- Norepinephrine, 17
- Norpramin. See *Desipramine*.
- Nortriptyline (Pamelor, others), 122t, 196t, 200t
- NRS. See *Numeric rating scale*.
- NSAIDs. See *Nonsteroidal anti-inflammatory drugs*.
- Nubain. See *Nalbuphine*.
- Nuclear medicine scanning, 52
- Nucynta. See *Tapentadol IR*.
- Numeric rating scale (NRS), 34-35, 34
- Nurses, 242-243
- Nutritional regimens/supplements, 175
  
- Occupational therapy, 167, 168
- Olanzapine, 129
- Older people, 211-217
  - changes in organ systems, 213t
  - guidelines for pharmacologic therapy, 214, 215t-216t
  - opioid use in, 214-217, 215t-216t
  - 100 days, first or golden, 27

- Onsolis. See *Fentanyl citrate*.
- Opana, Opana ER. See *Oxycodone*.
- Opioid Risk Tool (ORT), 42
- Opioids, 133-147, 136t-141t
  - abuse potential, 145t, 147
  - recognizing, 234-236
  - screening tools for, 41-43
  - abuse-resistant and -deterrent formulations, 236-237
  - actions of (agonist, antagonist, mixed), 134
  - administration routes/delivery methods, 134-135, 142, 147
    - cautions on, 142
    - neuraxial administration, 147
  - agents and dosages, 136t-141t
  - APAP-containing (Vicodin, Percocet), 116, 139t, 140t
  - APS-AAPM recommendations for use, 143, 144t-146t
  - cessation of therapy, 232
  - classes/characteristics of, 134
    - controlled-release (CR), 134, 137t-139t, 142-143, 237
    - extended-release (ER), 159-162, 160, 161, 163
    - fixed-dose combinations, 139t-141t
    - immediate-release (IR), 134, 135, 136t-137t, 156-159, 158, 159
    - long-acting, 134, 139t
    - ultra rapid-acting/topical, 134, 136t, 147, 154-156, 155, 156
  - indications and usages, 135, 136t-141t, 143
  - angina/MI, 93
  - cancer-related pain, 102, 103, 105, 206, 207, 223-224
    - breakthrough pain, 135, 136t, 146t, 207, 223
    - palliative care, 223-224
  - chronic noncancer pain, 143, 144t-146t
  - chronic opioid therapy (COT), 144t-146t
  - CRPS, 80
  - diabetic neuropathic pain, 200t
  - headache, 68, 127
  - herniated disk, 74, 187
  - low back pain, 189, 191
  - lumbar spinal stenosis, 74
  - neuropathic pain, 195, 196t
  - osteoarthritis, 82
  - pancreatitis, 98
  - pericarditis, 94
  - phantom limb pain, 90-91
  - pleuritis, 94
  - postherpetic neuralgia, 87, 88, 202, 202
  - medicolegal considerations, 146t, 147, 227-239
    - documentation, 233-234
    - FDA and FDAAA, 236-237
    - Federation of State Medical Boards requirements, 228-230
    - periodic reviews, 216t, 231-233
    - Risk Evaluation and Mitigation Strategies (REMS), 237
    - "universal precautions" for prescribing, 229-230

- Opioids (*continued*)  
 monitoring during use, 144t-145t  
 older people, use in, 214-217, 215t-216t  
 patient selection for, 144t, 145t  
 in pregnancy, 146t  
 receptor binding by, 134  
 side effects (constipation), 143-147, 145t, 207-208  
 sites of action of, 22, 23  
 6 or 7 A's of therapy, 232  
 useful publications for prescribers, 260
- Oramorph SR. See *Morphine, controlled-release*.
- Organizations. See *Societies and organizations*.
- Orphenadrine, 129, 130t
- ORT (Opioid Risk Tool), 42
- Orudis. See *Ketoprofen*.
- Oruvail. See *Ketoprofen-SR*.
- Osteoarthritis (OA), 81-83  
 treatment of, 82-83, 115
- Osteoporosis, 186
- Oucher Scale, 220
- Ovulatory/menstrual pain, 99-100
- Oxaprozin (Daypro), 119t
- Oxycodone, 134, 135, 142, 200t  
 controlled-release (OxyContin), 134, 138t, 142  
 fixed-dose combinations  
 oxycodone/APAP (Percocet, Endocet, others), 140t  
 oxycodone/aspirin (Percodan, Endodan), 140t  
 immediate-release, 134, 137t
- OxyContin. See *Oxycodone, controlled-release*.
- Oxygen, for cluster headache, 185
- Oxymorphone (Opana), 134, 135  
 controlled/extended-release (Opana ER), 139t, 159-160, 160  
 immediate-release, 137t  
 ultra rapid-acting, 136t
- Pain. See also *Acute pain; Chronic pain; Classification of pain*.  
 acute vs chronic, 26-27  
 causes of, 11-13, 12, 28-29  
 classification/types of, 11-13, 25-32  
 definition of, 11  
 placebos and, 31  
 processing mechanisms, 13-18, 14  
 reality of, 30-31  
 science of, 11-24  
 scope and burden of, ix-x  
 subacute or recurrent, 27
- PAIN (journal), 257
- Pain advocacy groups, 253-255
- Pain assessment. See *Assessment of pain*.
- Pain associations, organizations, and societies, 247-252
- Pain history, 45-46, 47t
- Pain intensity. See *Intensity of pain*.
- Pain journals/publications, 255-259
- Pain-management medicine, 227-228
- Pain Management Nursing* (journal), 257
- Pain-management specialists. See *Pain specialists*.
- Pain medicine (field of), 241-242
- Pain Medicine* (journal), 257
- Pain Medicine News* (journal), 259
- Pain Physician* (journal), 257
- Pain Practitioner, The* (journal), 258
- Pain processing mechanisms, 13-18, 14  
 brain, 18, 19  
 dorsal horn, 15-17, 16  
 neuroplasticity and, 18-20  
 nociceptive pain, 13-18, 14  
 second-order neurons, 15-16, 16, 17  
 sites of action for analgesic agents, 22, 23  
 transduction, 13-15, 14  
 transmission, 14, 15-17, 16
- Pain questionnaires, 36-37
- Pain Research & Management* (journal), 257-258
- Pain scales, 33-37, 34  
 categoric scales, 34, 35-36  
 FLACC Scale, 218, 219t  
 monodimensional, 33-36  
 numeric rating scale (NRS), 34-35, 34  
 Oucher Scale, 220  
 pictorial/faces scales, 34, 35-36, 220  
 questionnaires, 36-37  
 use with older people, 212  
 verbal descriptors, 34, 35  
 visual analogue scales (VAS), 34, 35
- Pain specialists, 241-246  
 functions of, 57, 243-244  
 pain medicine, field of, 241-242  
 referral to, 244-246  
 training and backgrounds of, 242-243
- Pain syndromes, 57-113. See also *specific syndromes*.  
 abdominal and pelvic pain, 95-100  
 arthropathies, 81-86  
 cancer-related pain, 102-105  
 cardiac/central chest pain, 92-94, 93t  
 central pain modification failure, 100-102  
 complex regional pain syndrome (CRPS), 79-80  
 extremity pain, 76-81  
 headache and neck pain, 58-68  
 low back pain, 68-76  
 neuropathies, 86-91  
 nonvascular pain, 94-95

Pain syndromes (*continued*)  
treatment of, 179-209. See also *Treatment of pain and pain syndromes*.  
vascular pain, 91-92  
Pain treatment. See *Treatment of pain and pain syndromes*.  
*Pain View* (journal), 258  
Palliative care, 28, 222-223  
Pamelor. See *Nortriptyline*.  
Pancreatic cancer, 103  
Pancreatitis, 98  
Papilledema, 70t  
Parafon Forte DSC. See *Chlorzoxazone*.  
Paraneoplastic syndromes, 104  
Paroxetine (Paxil, others), 121, 122t  
Pathology, pain classification by, 28-30  
Paxil. See *Paroxetine*.  
Pelvic pain, 99-100. See also *Abdominal and pelvic pain*.  
readings on, 112-113  
Pemoline, 133  
Pennsaid. See *Diclofenac*.  
Pentazocine (Talwin), 134, 141t, 143  
Pentazocine/APAP (Talacen), 141t  
Pentazocine/naloxone (Talwin NX), 141t  
Perception of pain, mechanisms involved in, 13-18, 14  
Percocet (oxycodone/APAP), 116, 140t  
Percodan (oxycodone/aspirin), 140t  
Pericarditis, 93-94  
Peripheral arteries, disorders of, 91-92  
peripheral artery disease (PAD), 91-92  
Raynaud's phenomenon, 92  
thromboangiitis obliterans, 92  
Peripheral artery disease (PAD), 91-92  
Peripheral neuropathy, 29. See also *Neuropathies*.  
Peripheral sensitization, 20, 21  
Peripheral (somatic) pain, 28  
Perphenazine, 129  
Phalen's maneuver, 76  
Phantom limb pain, 90-91, 113  
Pharmacologic agents, sites of action of, 22, 23  
Pharmacologic treatment of pain, 115-165. See also *specific drugs and classes of drugs*.  
acetaminophen, 115-116  
anti-inflammatory agents, 116-120  
anticonvulsants, 124-126, 125t  
antidepressants, 120-124, 122t-123t  
antimigraine agents, 127, 128t  
antipsychotics, 127-129  
antispastics/muscle relaxants, 129-131, 130t  
anxiolytics, 126-127  
combination-medication approach, 22

Pharmacologic treatment of pain (*continued*)  
controlled-substance prescribing. See *Medicolegal considerations*.  
intrathecal drug delivery, 174-175  
local anesthetics, 131-133  
new agents and indications, 147-162  
diabetic peripheral neuropathic pain, 150-152, 152, 153  
extended-release opioids, 159-162, 160, 161, 163  
fibromyalgia, 147-150, 148, 149  
immediate-release opioids, 156-159, 158, 159  
rapid-acting opioids, 154-156, 155, 156  
in older people, 213-217, 215t-216t  
opioids, 133-147, 136t-141t  
overview, 115  
periodic reviews of, 216t, 231-233  
psychostimulants, 133  
Phenothiazine agents, 129  
Phenytoin, 201, 202  
PHN. See *Postherpetic neuralgia*.  
Physical examination, 46, 48t-49t  
Physical medicine pain specialists, 243-244, 245  
Physical/occupational therapy, 167, 168  
Physicians, resources for. See *Resources*.  
Physician-specialists. See *Pain specialists*.  
Piroxicam (Feldene), 119t  
Placebos, 31  
Pleuritis, 94  
Plexopathy, 90, 104  
Pneumococcal vaccination, 84  
Pneumothorax, 94  
Polyneuropathy, 88  
Postherpetic neuralgia (PHN), 87-88, 201  
treatment options, 201-202, 202  
antidepressants, 121, 201, 202  
calcium channel modulators, 125t, 126, 201, 202  
capsaicin, 132-133, 201-202, 202  
lidocaine, 132, 201, 202  
PQRST mnemonic, 46  
*Practical Pain Management* (journal), 258  
Practitioners, resources for. See *Resources*.  
Prednisone, 184  
Prefrontal cortex, 18, 19  
Pregabalin (Lyrica), 125t, 126  
indications and usages  
diabetic peripheral neuropathic pain, 152, 153, 200, 200t  
fibromyalgia, 125t, 126, 147-148, 148, 149  
neuropathic pain, 196t  
postherpetic neuralgia, 87, 126, 201, 202  
Pregnancy  
ectopic, pain of, 99  
headache in, 70t

- Pregnancy (*continued*)  
 opioid use during, 146t  
 TENS contraindication during, 169
- Prescriber responsibilities, 230-233
- Prilocaine, 131
- Prisons, treatment of individuals in, 224-225
- Pristiq. See *Desvenlafaxine*.
- Procaine, 131
- Processing of pain. See *Pain processing mechanisms*.
- Pronator syndrome, 77-78
- Propoxyphene (Darvon), 135, 137t
- Propoxyphene/APAP (Darvocet), 141t
- Propranolol, 183, 184
- Prostaglandin E<sub>2</sub> (PGE<sub>2</sub>), 20, 21  
 for peripheral artery disorders, 91
- Prostaglandin receptor (EP), 20, 21
- Protein kinases, 16, 20
- Proton pump inhibitors, 215t
- Prozac. See *Fluoxetine*.
- Psychiatrists and psychologists, 244, 245
- Psychological/behavioral interventions, 167, 171
- Psychosocial assessment, 54-55, 55t
- Psychosocial risk factors, in chronic pain, 54-55, 55t
- Psychostimulants, 133
- Quantitative sensory testing (QST), 50
- Questionnaires, 36-37
- Quetiapine, 129
- Qutenza (capsaicin patch), 133, 201-202, 202
- Race Against Pain, 254
- Racial minorities, 222-223
- Radial tunnel syndrome, 78
- Radiation-induced pain, 104-105
- Radiation neuropathy, 90
- Radicular pain, 68-73, 187-190  
 SCS for, 173
- Radiography, 50
- Rating scales for pain, 33-37, 34
- Raynaud's phenomenon, 92
- Reactive arthritis, 84-85
- Recurrent acute pain, 27
- Referral to pain-management specialist, 244-246. See also *Pain specialists*.  
 for chronic low back pain, 191, 192-193
- Reflex sympathetic dystrophy. See *Complex regional pain syndrome, type 1*.
- Reflex Sympathetic Dystrophy Syndrome Association (RSDSA), 252
- Regional Anesthesia and Pain Medicine* (journal), 258
- Regulations. See *Medicolegal considerations*.
- Rehabilitation. See *Nonpharmacologic and interventional therapies*.
- Relafen. See *Nabumetone*.
- Relpax. See *Eletriptan*.
- Repetitive stress/strain  
 carpal tunnel syndrome, 76-77, 203-204  
 cubital tunnel syndrome, 78  
 pronator syndrome, 77-78  
 radial tunnel syndrome, 78  
 readings on, 113  
 tarsal tunnel syndrome, 78-79
- Repetitive stress/strain syndromes, 76-79
- Resources for practitioners, 247-263  
 annual pain meetings (US), 259  
 associations, organizations, and societies, 247-252  
 books on pain (non-textbook), 261  
 disease/syndrome-specific organizations, 251-252  
 pain advocacy groups, 253-255  
 pain journals/publications, 255-259  
 pain textbooks, 260  
 pain web sites (pharmaceutical-supported), 262-263  
 publications for opioid prescribers, 260
- Rheumatoid arthritis (RA), 83-84
- Risk Evaluation and Mitigation Strategies (REMS), 237
- Risperidone, 129
- Rizatriptan (Maxalt, Maxalt-MLT), 127, 128t
- Ropivacaine, 131
- Ryzolt. See *Tramadol, controlled-release*.
- Sacroiliac joint dysfunction, 75-76
- Salicylates, 116-117, 118t
- Savella. See *Milnacipran*.
- Scales. See also *Depression, assessment of; Pain scales*.  
 anxiety, 39  
 depression, 37-39  
 pain, 33-37, 34, 212
- Screener and Opioid Assessment for Patients with Pain (SOAPP), 42-43
- SCS. See *Spinal cord stimulation*.
- Second-order neurons, 15-16, 16, 17
- Selective serotonin reuptake inhibitors (SSRIs), 121, 122t. See also *Duloxetine; Milnacipran*.  
 for neuropathic pain, 195, 196t, 200, 200t  
 for postherpetic neuralgia, 201, 202
- Self-reporting pain assessments, 33-37, 34
- Sensitization  
 central, 16-17  
 peripheral, 20, 21
- Serotonin, 17
- Serotonin and norepinephrine reuptake inhibitors (SNRIs), 121-124, 123t

Serotonin antagonists, for headache, 68, 127  
 Sertraline (Zoloft, others), 122t  
 Shingles, 87  
 Short Form Health Survey (SF36), 54  
 Sinequan. See *Doxepin*.  
 Skelaxin. See *Metaxalone*.  
 SNRIs. See *Serotonin and norepinephrine reuptake inhibitors*.  
 SOAPP (Screener and Opioid Assessment for Patients with Pain), 42-43  
 Social workers, 244, 245  
 Societies and organizations, 247-252. See also *Resources*.  
 Society for Pain Practice Management (SPPM), 250  
 Sodium channel blockers/modulators, 22, 23, 125t, 201, 202  
 Sodium channels, expression of, 20, 21  
 Soft tissue pain, cancer-related, 103  
 Solaraze. See *Diclofenac*.  
 Soma. See *Carisoprodol*.  
 Somatic pain, 28, 29  
   treatment of, 29  
 Somatosensory evoked potentials (SSEP), 50  
 Special-needs populations, 221-226  
   children and adolescents, 217-222  
   ethnic and racial minorities, 222-223  
   older people, 211-217  
   other, 224-225  
     dual-diagnosis, 224  
     incarcerated individuals, 224-225  
     military personnel with combat trauma, 224  
   terminally ill cancer patients, 223-224  
 Specialists. See *Pain specialists*.  
 Spinal cord, pain processing in, 13-17, 14, 16  
 Spinal cord compression, 102-103  
 Spinal cord stimulation (SCS), 80, 173, 197  
 Spinal fractures, 186-190, 188-189  
 Spinal nerve roots  
   compression of, 72-73  
   pain of, 68-76  
   surgical denervation, 174  
 Spinoparabrachial tracts, 15  
 Spinothalamic tracts, 15  
 Spondyloarthropathies, 84-85  
 Spondylolysis/spondylolisthesis, 188-189  
 Spontaneous pain, 12, 13  
 SSRIs. See *Selective serotonin reuptake inhibitors*.  
 Stadol. See *Butorphanol*.  
 States, authority of, 227  
 Steroid injections, 172, 204  
   epidural, 74, 172  
   joint, 82, 172  
 Steroids, for reactive arthritis, 172

Stool softeners, 143-147, 208  
 Subacute pain, 27  
 Substance abuse. See also *Medicolegal considerations*.  
   assessment of abuse/potential, 39-43  
     CAGE-AID, 40-41  
     Diagnosis, Intractability, Risk, and Efficacy (DIRE) Score, 41-42  
     Drug Abuse Screening Test (DAST), 41  
     Michigan Alcoholism Screening Test (MAST), 41  
     Opioid Risk Tool (ORT), 42  
     Screener and Opioid Assessment for Patients with Pain (SOAPP), 42-43  
   potential in children and adolescents, 221  
   potential in minority populations, 222  
   recognizing potential for, 234-236  
   Risk Evaluation and Mitigation Strategies (REMS), 237  
     urine test for, 54, 234  
 Substance P, 15, 16, 17, 132  
 Sufentanil, 147  
 Sulfasalazine, 84  
 Sulindac (Clinoril), 119t  
 Sumatriptan (Imitrex), 127, 128t, 184, 185  
 Sumatriptan/naproxen (Treximet), 127, 128t  
 Surgical denervation, 174  
 Sympathectomy, 197  
 Sympathetically maintained pain, 28, 31, 113  
  
 Take-away messages. See *End of each chapter*.  
 Talacen (pentazocine/APAP), 141t  
 Talwin. See *Pentazocine*.  
 Talwin NX (pentazocine/naloxone), 141t  
 Tapentadol, tapentadol IR (Nucynta), 135, 137t, 156-159  
   vs oxycodone, 157-159, 158, 159  
 Tarsal tunnel syndrome, 78-79  
 Technetium scans, 52  
*Techniques in Regional Anesthesia and Pain Management*  
   (journal), 258  
 Tegretol, Tegretol-XR. See *Carbamazepine*.  
 Temporomandibular joint disorder (TMJ), 101  
   treatment of, 131  
 Tender points, 100  
 TENS. See *Transcutaneous electrical nerve stimulation*.  
 Tension-type headache, 64, 64t  
   treatment of, 182  
 Tests. See *Evaluation and diagnosis*.  
 Tetracaine, 131  
 Textbooks on pain, 260  
 Thalamus, 18, 19  
 Thermal modalities, 168-169  
   heat/ice packs, 168  
 Thoracic outlet syndrome, 80-81, 113

- Thromboangiitis obliterans, 92
- “Thunderclap” headache, 61, 70t, 179
- Time course, classification of pain by, 26-27
- Timolol, 183
- Tinel’s sign, 76
- Tizanidine (Zanaflex, others), 130t, 131
- TMJ. See *Temporomandibular joint disorder*.
- TNF. See *Tumor necrosis factor*.
- Tofranil-PM. See *Imipramine*.
- Tolectin. See *Tolmetin*.
- Tolmetin (Tolectin), 119t
- Topamax. See *Topiramate*.
- Topiramate (Topamax), 125t, 126
- Toxic neuropathies, 88-89, 89t
- Tramadol, 135
  - controlled-release (Ultram ER, Ryzolt), 139t
  - fixed-dose combination (tramadol/APAP, Ultracet), 141t
  - immediate-release (Ultram), 137t
  - indications and usages, 137t
    - neuropathic pain, 195, 196t, 200t
    - postherpetic neuralgia, 88, 202
- Tranquilizers
  - major (antipsychotics), 127-129
  - minor (anxiolytics), 126-127
- Transcutaneous electrical nerve stimulation (TENS), 168, 169-170, 195, 200
  - contraindications and cautions, 169
- Transduction of pain, 13-15, 14
  - analgesic medications and, 23
- Transmission of pain, 14, 15-17, 16
  - analgesic medications and, 23
- Trazodone (Desyrel), 123t, 124
- Treatment of pain and pain syndromes, 179-209. See also *specific syndromes and pain conditions*.
  - back pain, 185-191
  - cancer pain, 205-208, 206
  - chronic pain, 27
  - compliance with, 54
  - documentation of, 233-234
  - entrapment neuropathies, 203-204
  - failure of descending inhibitory control, 29
  - general guidelines, 29-30
  - headache, 179-185, 180-181, 184
  - medication history, 46, 47t
  - medicolegal considerations, 227-239
  - neuropathic pain, 194-202
  - nonpharmacologic treatment, 167-178. See also *Nonpharmacologic and interventional therapies*.
  - periodic reviews of, 216t, 231-233
  - Treatment of pain and pain syndromes (*continued*)
    - pharmacologic treatment, 115-165. See also *Pharmacologic treatment of pain*.
    - special-needs populations, 221-226
      - children and adolescents, 217-222
      - ethnic and racial minorities, 222-223
      - older people, 211-217
      - terminally ill cancer patients, 223-224
  - Treximet. See *Sumatriptan/naproxen*.
  - Triamcinolone, 120
  - Tricyclic antidepressants (TCAs), 120-121
    - agents and dosages, 122t
    - indications and usages
      - AIDS-related neuropathies, 88
      - headache, 68, 127
      - neuropathic pain, 121, 195, 196t, 200t
      - postherpetic neuralgia, 88, 202t
      - older people, cautions for use in, 216t
  - Trigeminal neuralgia, 125t, 126, 194
  - Trigger-point injections, 171-172
  - Triptans, 128t
    - for headache, 68, 127, 183, 184
  - TrkB receptors, 17
  - Tumor necrosis factor (TNF), 20, 21
  - Tumor necrosis factor (TNF) inhibitors
    - for reactive arthritis, 85
    - for rheumatoid arthritis, 84
  - Tylenol. See *Acetaminophen*.
  - Types of pain. See *Classification of pain*.
- Ulcerative colitis, 95
- Ulnar tunnel syndrome, 204
- Ultracet (tramadol/APAP), 141t
- Ultram. See *Tramadol*.
- Ultrasonography, 52
- Ultrasound therapy, 168
- Universal precautions, for prescribing opioids, 229-230
- Urine test, 54, 234
- Vaccinations, 84
- Valproic acid, 126, 184
- VAS. See *Visual analogue scales*.
- Vascular headaches, 62-64, 182-185
  - treatment of, 183-185, 184
- Vascular pain, 91-92, 113
- Venlafaxine (Effexor), 121, 123t, 196t
  - hypertensive potential of, 124
- Verapamil, 184
- Vicodin (hydrocodone/APAP), 116, 140t. See also *Hydrocodone*.
- Vicoprofen (hydrocodone/ibuprofen), 140t

Visceral pain, 29  
Visual analogue scales (VAS), 34, 35  
Vitamins, for headache, 68, 127  
Voltaren formulations. See *Diclofenac*.  
Vulvodynia, 102  
    national association for, 252

Web sites (pharmaceutical-supported), 262-263  
Wellbutrin formulations. See *Bupropion*.  
Withdrawal responses, 14, 15  
Wong-Baker Faces Rating Scale, 34, 35-36, 220  
World Health Organization (WHO), Three-Step Analgesic Ladder,  
    205-207, 206

X-rays, 50

Zaleplon, 127  
Zanaflex. See *Tizanidine*.  
Ziconotide, 175  
Ziprasidone, 129  
Zipsor. See *Diclofenac*.  
Zolmitriptan (Zomig, Zomig-ZMT), 128t  
Zolof. See *Sertraline*.  
Zolpidem, 127  
Zomig, Zomig-ZMT. See *Zolmitriptan*.  
Zoster, 87, 201  
Zung Self-Rating Depression Scale, 38-39  
Zydone (hydrocodone/APAP), 140t